Genmab A/S (GMAB) News Today $20.33 +0.15 (+0.74%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GMAB Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Genmab AS ADR GMABMay 20 at 10:21 PM | morningstar.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseMay 20 at 12:01 PM | globenewswire.comTema Etfs LLC Acquires New Position in Genmab A/S (NASDAQ:GMAB)Tema Etfs LLC acquired a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 58,935 shares of the company's stock, valued at approximately $1,230,000. AMay 20 at 6:16 AM | marketbeat.comGenmab A/S (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from AnalystsGenmab A/S (NASDAQ:GMAB - Get Free Report) has earned a consensus rating of "Moderate Buy" from the thirteen analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating aMay 20 at 2:34 AM | marketbeat.comTransactions in Connection with Share Buy-back ProgramMay 19 at 9:08 AM | globenewswire.comBNP Paribas Financial Markets Invests $2.55 Million in Genmab A/S (NASDAQ:GMAB)BNP Paribas Financial Markets bought a new position in Genmab A/S (NASDAQ:GMAB - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 122,373 shares of the company's stock, valued at approximately $2,554,000. A number of otMay 19 at 3:39 AM | marketbeat.comNorthern Trust Corp Increases Stock Position in Genmab A/S (NASDAQ:GMAB)Northern Trust Corp boosted its stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 18.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 599,381 shares of the company's stock after buying anMay 19 at 3:17 AM | marketbeat.comPoint72 Hong Kong Ltd Takes Position in Genmab A/S (NASDAQ:GMAB)Point72 Hong Kong Ltd purchased a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 43,671 shares of the company's stock, valued at approximately $911,000. A number oMay 18 at 6:14 AM | marketbeat.comDimensional Fund Advisors LP Sells 24,894 Shares of Genmab A/S (NASDAQ:GMAB)Dimensional Fund Advisors LP lessened its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 35.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 45,615 shares of the company's stock after selling 24,894 shares during the period. DimensiMay 18 at 3:05 AM | marketbeat.comQ2 Earnings Estimate for Genmab A/S Issued By HC WainwrightMay 18 at 1:57 AM | americanbankingnews.comCresset Asset Management LLC Reduces Stock Position in Genmab A/S (NASDAQ:GMAB)Cresset Asset Management LLC lessened its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 56.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 25,752 shares of the company's stock after selling 33,523 shares duMay 17, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Bought by Graham Capital Management L.P.Graham Capital Management L.P. raised its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 38.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 55,417 shares of the company's stock after acquiring an additional 15,321 shares during the period. Graham CapitMay 15, 2025 | marketbeat.comGenmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) CongressMay 14, 2025 | globenewswire.comGenmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) CongressMay 14, 2025 | businesswire.comHudson Bay Capital Management LP Has $11.27 Million Stock Holdings in Genmab A/S (NASDAQ:GMAB)Hudson Bay Capital Management LP lifted its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 103.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 540,000 shares of the company's stock afMay 14, 2025 | marketbeat.comFY2027 EPS Estimates for Genmab A/S Lowered by William BlairGenmab A/S (NASDAQ:GMAB - Free Report) - William Blair lowered their FY2027 earnings per share (EPS) estimates for Genmab A/S in a research note issued on Friday, May 9th. William Blair analyst M. Phipps now anticipates that the company will earn $2.58 per share for the year, down from their prioMay 14, 2025 | marketbeat.comGenmab reports share buy-back transactionsMay 13, 2025 | investing.comLeerink Partnrs Increases Earnings Estimates for Genmab A/SMay 13, 2025 | americanbankingnews.comLeerink Partnrs Expects Increased Earnings for Genmab A/SGenmab A/S (NASDAQ:GMAB - Free Report) - Investment analysts at Leerink Partnrs upped their FY2025 earnings per share estimates for Genmab A/S in a note issued to investors on Thursday, May 8th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings per share of $1.6May 13, 2025 | marketbeat.comTransactions in Connection with Share Buy-back ProgramMay 12, 2025 | globenewswire.comJane Street Group LLC Takes Position in Genmab A/S (NASDAQ:GMAB)Jane Street Group LLC bought a new position in Genmab A/S (NASDAQ:GMAB - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 263,403 shares of the company's stock, valued at approximately $5,497,000. Other institutMay 12, 2025 | marketbeat.comGenmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic InitiativesMay 9, 2025 | finance.yahoo.comDeep Track Capital LP Invests $41.74 Million in Genmab A/S (NASDAQ:GMAB)Deep Track Capital LP acquired a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,000,000 shares of the company's stock, valued at appMay 9, 2025 | marketbeat.com592,250 Shares in Genmab A/S (NASDAQ:GMAB) Acquired by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC bought a new position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 592,250 shares of the company's stock, valued atMay 9, 2025 | marketbeat.comGenmab A/S (GMAB) Q1 2025 Earnings Conference Call TranscriptMay 8, 2025 | seekingalpha.comGenmab Announces Financial Results for the First Quarter of 2024May 8, 2025 | globenewswire.com291,500 Shares in Genmab A/S (NASDAQ:GMAB) Bought by Bridger Management LLCBridger Management LLC bought a new position in Genmab A/S (NASDAQ:GMAB - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 291,500 shares of the company's stock, valued at approximately $6,084,000. GMay 8, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Sold by Bamco Inc. NYBamco Inc. NY decreased its stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 56.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,691 shares of the company's stock after selling 40,683May 8, 2025 | marketbeat.comStifel Financial Corp Sells 60,816 Shares of Genmab A/S (NASDAQ:GMAB)Stifel Financial Corp trimmed its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 36.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 108,175 shares of the company's stock after selling 60,816 sharesMay 7, 2025 | marketbeat.comTransactions in Connection with Share Buy-back ProgramMay 5, 2025 | globenewswire.comGenmab A/S (GMAB) Projected to Post Quarterly Earnings on ThursdayGenmab A/S (NASDAQ:GMAB) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-genmab-as-stock/)May 3, 2025 | marketbeat.comRaymond James Financial Inc. Makes New $2.46 Million Investment in Genmab A/S (NASDAQ:GMAB)Raymond James Financial Inc. bought a new stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 118,002 shares of the company's stock, valued at apMay 2, 2025 | marketbeat.comGenmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)May 1, 2025 | businesswire.comGenmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)May 1, 2025 | globenewswire.comOptiver Holding B.V. Takes $757,000 Position in Genmab A/S (NASDAQ:GMAB)Optiver Holding B.V. purchased a new position in Genmab A/S (NASDAQ:GMAB - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 36,260 shares of the company's stock, valued at approximately $757,000. Other large investors also recentlMay 1, 2025 | marketbeat.comFY2025 EPS Estimates for Genmab A/S Boosted by HC WainwrightGenmab A/S (NASDAQ:GMAB - Free Report) - Stock analysts at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for Genmab A/S in a report issued on Thursday, April 24th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $1.58 per share forApril 29, 2025 | marketbeat.comTransactions in Connection with Share Buy-back ProgramApril 28, 2025 | globenewswire.comQ1 Earnings Forecast for Genmab A/S Issued By HC WainwrightGenmab A/S (NASDAQ:GMAB - Free Report) - Equities research analysts at HC Wainwright upped their Q1 2025 earnings per share estimates for shares of Genmab A/S in a research report issued to clients and investors on Thursday, April 24th. HC Wainwright analyst R. Selvaraju now anticipates that theApril 27, 2025 | marketbeat.comFirst Trust Advisors LP Buys 251,241 Shares of Genmab A/S (NASDAQ:GMAB)First Trust Advisors LP lifted its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 18.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,644,288 shares of the company's stoApril 27, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Receives Consensus Rating of "Moderate Buy" from BrokeragesGenmab A/S (NASDAQ:GMAB - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the thirteen research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold ratiApril 26, 2025 | marketbeat.comCapital International Investors Lowers Stake in Genmab A/S (NASDAQ:GMAB)Capital International Investors lessened its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 41.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,570,909 shares of the company's stock after selling 1,850,708 shares during the qApril 23, 2025 | marketbeat.comTransactions in Connection with Share Buy-back ProgramApril 22, 2025 | globenewswire.comMarshall Wace LLP Acquires 694,243 Shares of Genmab A/S (NASDAQ:GMAB)Marshall Wace LLP increased its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 162.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,122,296 shares of the company's stock after purchApril 22, 2025 | marketbeat.comBank of Montreal Can Decreases Stake in Genmab A/S (NASDAQ:GMAB)Bank of Montreal Can cut its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 57.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 32,109 shares of the company's stock after selling 43,71April 22, 2025 | marketbeat.comWells Fargo & Company MN Lowers Stake in Genmab A/S (NASDAQ:GMAB)Wells Fargo & Company MN cut its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 59.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 283,111 shares of the company's stock after selling 417,293 shares during the quarApril 21, 2025 | marketbeat.comShort Interest in Genmab A/S (NASDAQ:GMAB) Drops By 29.7%Genmab A/S (NASDAQ:GMAB - Get Free Report) saw a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 2,150,000 shares, a drop of 29.7% from the March 15th total of 3,060,000 shares. Approximately 0.3% of the company's stock are short sold. Based on an average daily trading volume, of 1,590,000 shares, the days-to-cover ratio is presently 1.4 days.April 20, 2025 | marketbeat.comBrokers Offer Predictions for Genmab A/S FY2025 EarningsGenmab A/S (NASDAQ:GMAB - Free Report) - Research analysts at William Blair cut their FY2025 earnings per share estimates for shares of Genmab A/S in a research note issued on Monday, April 14th. William Blair analyst M. Phipps now expects that the company will post earnings per share of $1.29 foApril 19, 2025 | marketbeat.comWilliam Blair Has Negative Outlook of Genmab A/S Q1 EarningsGenmab A/S (NASDAQ:GMAB - Free Report) - Investment analysts at William Blair dropped their Q1 2025 earnings estimates for Genmab A/S in a report released on Monday, April 14th. William Blair analyst M. Phipps now expects that the company will post earnings per share of $0.17 for the quarter, dowApril 18, 2025 | marketbeat.comEnvestnet Asset Management Inc. Has $15.11 Million Holdings in Genmab A/S (NASDAQ:GMAB)Envestnet Asset Management Inc. decreased its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 30.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 723,781 shares of the company's stock after selling 319,779 shares durApril 17, 2025 | marketbeat.comJPMorgan Chase & Co. Boosts Stock Holdings in Genmab A/S (NASDAQ:GMAB)JPMorgan Chase & Co. lifted its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 3,049.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 407,613 shares of the company's stock after purchasing an additional 394,670 shares during the period. JPMorgan Chase &April 17, 2025 | marketbeat.com Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address GMAB Media Mentions By Week GMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GMAB News Sentiment▼0.700.65▲Average Medical News Sentiment GMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GMAB Articles This Week▼246▲GMAB Articles Average Week Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News Today argenx News Today BioNTech News Today Beigene News Today Teva Pharmaceutical Industries News Today Summit Therapeutics News Today Intra-Cellular Therapies News Today Dr. Reddy's Laboratories News Today Viatris News Today Moderna News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GMAB) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GMAB Stock Free GMAB Stock Alerts